Characterizing Pharmacokinetics in Children With Obesity—Physiological, Drug, Patient, and Methodological ConsiderationsJacqueline G. Gerhart, Daniel González, Stephen J. Balevic et al.|Frontiers in Pharmacology|2022Cited by 40
Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic ModelingJacqueline G. Gerhart, Robert H. Lurie, Phyllis Kennel et al.|Clinical Pharmacokinetics|2021Cited by 39
Use of Real‐World Data and Physiologically‐Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With ObesityJacqueline G. Gerhart, Daniel González, Fernando Carreño et al.|Clinical Pharmacology & Therapeutics|2022Cited by 30
Pediatric Drug‐Drug Interaction Evaluation: Drug, Patient Population, and Methodological ConsiderationsDaniel González, Jaydeep Sinha|The Journal of Clinical Pharmacology|2021Cited by 26
Physiologically‐based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescentsJaydeep Sinha, Daniel González, Eleni Karatza|CPT Pharmacometrics & Systems Pharmacology|2021Cited by 19